伊伐布雷定在儿童心血管疾病中的应用进展  

Research progress in the application of ivabradine in children with cardiovascular diseases

作　　者：蒋露(综述) 孙慧超(审校)[1] JIANG Lu;SUN Hui-Chao(Department of Cardiology,Children's Hospital of Chongqing Medical University/National Key Clinical Specialty/Ministry of Education Key Laboratory of Child Development and Disorders/National Clinical Research Center for Child Health and Disorders/China International Science and Technology Cooperation Base of Child Development and Critical Disorders,Chongqing 400014,China)

机构地区：[1]重庆医科大学附属儿童医院心血管科/国家临床重点专科/儿童发育疾病研究教育部重点实验室/国家儿童健康与疾病临床医学研究中心/儿童发育重大疾病国家国际科技合作基地,重庆400014

出　　处：《中国当代儿科杂志》2024年第7期782-788,共7页Chinese Journal of Contemporary Pediatrics

基　　金：中华国际医学交流基金会中华心血管病发展专项基金(Z-2019-42-1908-2)。

摘　　要：伊伐布雷定作为特异性I_(f)电流抑制剂,因其在降低心率的同时不影响心肌收缩力和血压,已广泛应用于成人慢性心力衰竭的治疗,并且在多种快速性心律失常中亦展现出良好的治疗效果。但伊伐布雷定在儿童心血管疾病的应用还有很多限制,该文就目前国内外关于伊伐布雷定治疗儿童心血管疾病的研究进展进行综述,以期为儿童心血管医生提供指导。Ivabradine,as a specific I_(f) current inhibitor,has been widely used in the treatment of chronic heart failure in adults due to its ability to reduce heart rate without affecting myocardial contractility and blood pressure.It has also shown good effects in various types of tachyarrhythmias.However,the application of ivabradine in pediatric cardiovascular diseases still faces many limitations.This article reviews the current research progress on the use of ivabradine in treating pediatric cardiovascular diseases both domestically and internationally,aiming to provide guidance for pediatric cardiologists.

关 键 词：心力衰竭 伊伐布雷定 心律失常 心脏移植 儿童 

分 类 号：R725.4[医药卫生—儿科]